A FIRST-IN-HUMAN STUDY OF THE SECOND-GENERATION, THIN-STRUT, EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLD: 6-MONTH IVUS AND OCT RESULTS FROM THE FAST CLINICAL TRIAL

Authors :: Yasuhiro Honda
Masayasu Ikutomi
Darren Walters
Thomas Christen
Robert Whitbourn
Paul G. Yock
Jamie Layland
Jim Stewart
Sujith Seneviratne
Kozo Okada
Ian Meredith
Peter J. Fitzgerald
Ryo Kameda
M. Brooke Hollak
Seif El-Jack
Andrejs Erglis
Jeffrey J. Popma
Source :: Journal of the American College of Cardiology. 73:1111
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.
Abstract: In second-generation bioresorbable scaffolds, thinner struts are often adopted to improve both deliverability and safety profiles, while theoretical concerns remain regarding radial strength and fracture resistance. This analysis aimed to evaluate acute and mid-term performance of the RENUVIA

Subjects :: Clinical trial
Everolimus
business.industry
medicine
First in human
Cardiology and Cardiovascular Medicine
business
Bioresorbable scaffold
medicine.drug
Biomedical engineering

Full Text Access

Tools